́-lipoic acid regulates lipid metabolism through induction of Sirtuin 1 (SIRT1) and activation of AMP-activated protein kinase

W. L. Chen, C. H. Kang, S. G. Wang, H. M. Lee

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Aims/hypothesis Sirtuin 1 (SIRT1) is a longevity-associated protein, which regulates energy metabolism and lifespan in response to nutrient deprivation. It has been proposed to be a therapeutic target for obesity and metabolic syndrome. We investigated whether á-lipoic acid (ALA) exerts a lipidlowering effect through regulation of SIRT1 activation and production in C2C12 myotubes. Methods ALA-stimulated AMP-activated protein kinase (AMPK), acetyl-CoA carboxylase (ACC), adipose triacylglycerol lipase (ATGL) and fatty acid synthase (FAS) production, as well as intracellular triacylglycerol accumulation and fatty acid β-oxidation were analysed in the absence or presence of a SIRT1 inhibitor (nicotinamide), SIRT1 small interfering (si) RNA and an AMPK inhibitor (compound C) in C2C12 myotubes. Mice with streptozotocin/nicotinamideinduced diabetes and db/db mice fed on a high-fat diet were used to study the ALA-mediated lipid-lowering effects in vivo. Results ALA increased the NAD+/NADH ratio to enhance SIRT1 activity and production in C2C12 myotubes. ALA subsequently increased AMPK and ACC phosphorylation, leading to increased palmitate β-oxidation and decreased intracellular triacylglycerol accumulation in C2C12 myotubes. In cells treated with nicotinamide or transfected with SIRT1 siRNA, ALA-mediated AMPK/ACC phosphorylation, intracellular triacylglycerol accumulation and palmitate β-oxidation were reduced, suggesting that SIRT1 is an upstream regulator of AMPK. ALA increased ATGL and suppressed FAS protein production in C2C12 myotubes. Oral administration of ALA in diabetic mice fed on a high-fat diet and db/db mice dramatically reduced the body weight and visceral fat content. Conclusions/interpretation ALA activates both SIRT1 and AMPK, which leads to lipid-lowering effects in vitro and in vivo. These findings suggest that ALA may have beneficial effects in the treatment of dyslipidaemia and obesity.

Original languageEnglish
Pages (from-to)1824-1835
Number of pages12
JournalDiabetologia
Volume55
Issue number6
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Sirtuin 1
Thioctic Acid
AMP-Activated Protein Kinases
Lipid Metabolism
Skeletal Muscle Fibers
Acetyl-CoA Carboxylase
Fatty Acid Synthases
Triglycerides
Niacinamide
Palmitates
High Fat Diet
Lipase
NAD
Small Interfering RNA
Obesity
Phosphorylation
eIF-2 Kinase
Lipids
Experimental Diabetes Mellitus
Intra-Abdominal Fat

Keywords

  • ́-lipoic acid
  • AMPK
  • ATGL
  • SIRT1

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

́-lipoic acid regulates lipid metabolism through induction of Sirtuin 1 (SIRT1) and activation of AMP-activated protein kinase. / Chen, W. L.; Kang, C. H.; Wang, S. G.; Lee, H. M.

In: Diabetologia, Vol. 55, No. 6, 06.2012, p. 1824-1835.

Research output: Contribution to journalArticle

Chen, W. L. ; Kang, C. H. ; Wang, S. G. ; Lee, H. M. / ́-lipoic acid regulates lipid metabolism through induction of Sirtuin 1 (SIRT1) and activation of AMP-activated protein kinase. In: Diabetologia. 2012 ; Vol. 55, No. 6. pp. 1824-1835.
@article{c43bb5dbab8e4dd994eb1c111f40329d,
title = "́-lipoic acid regulates lipid metabolism through induction of Sirtuin 1 (SIRT1) and activation of AMP-activated protein kinase",
abstract = "Aims/hypothesis Sirtuin 1 (SIRT1) is a longevity-associated protein, which regulates energy metabolism and lifespan in response to nutrient deprivation. It has been proposed to be a therapeutic target for obesity and metabolic syndrome. We investigated whether {\'a}-lipoic acid (ALA) exerts a lipidlowering effect through regulation of SIRT1 activation and production in C2C12 myotubes. Methods ALA-stimulated AMP-activated protein kinase (AMPK), acetyl-CoA carboxylase (ACC), adipose triacylglycerol lipase (ATGL) and fatty acid synthase (FAS) production, as well as intracellular triacylglycerol accumulation and fatty acid β-oxidation were analysed in the absence or presence of a SIRT1 inhibitor (nicotinamide), SIRT1 small interfering (si) RNA and an AMPK inhibitor (compound C) in C2C12 myotubes. Mice with streptozotocin/nicotinamideinduced diabetes and db/db mice fed on a high-fat diet were used to study the ALA-mediated lipid-lowering effects in vivo. Results ALA increased the NAD+/NADH ratio to enhance SIRT1 activity and production in C2C12 myotubes. ALA subsequently increased AMPK and ACC phosphorylation, leading to increased palmitate β-oxidation and decreased intracellular triacylglycerol accumulation in C2C12 myotubes. In cells treated with nicotinamide or transfected with SIRT1 siRNA, ALA-mediated AMPK/ACC phosphorylation, intracellular triacylglycerol accumulation and palmitate β-oxidation were reduced, suggesting that SIRT1 is an upstream regulator of AMPK. ALA increased ATGL and suppressed FAS protein production in C2C12 myotubes. Oral administration of ALA in diabetic mice fed on a high-fat diet and db/db mice dramatically reduced the body weight and visceral fat content. Conclusions/interpretation ALA activates both SIRT1 and AMPK, which leads to lipid-lowering effects in vitro and in vivo. These findings suggest that ALA may have beneficial effects in the treatment of dyslipidaemia and obesity.",
keywords = "́-lipoic acid, AMPK, ATGL, SIRT1",
author = "Chen, {W. L.} and Kang, {C. H.} and Wang, {S. G.} and Lee, {H. M.}",
year = "2012",
month = "6",
doi = "10.1007/s00125-012-2530-4",
language = "English",
volume = "55",
pages = "1824--1835",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - ́-lipoic acid regulates lipid metabolism through induction of Sirtuin 1 (SIRT1) and activation of AMP-activated protein kinase

AU - Chen, W. L.

AU - Kang, C. H.

AU - Wang, S. G.

AU - Lee, H. M.

PY - 2012/6

Y1 - 2012/6

N2 - Aims/hypothesis Sirtuin 1 (SIRT1) is a longevity-associated protein, which regulates energy metabolism and lifespan in response to nutrient deprivation. It has been proposed to be a therapeutic target for obesity and metabolic syndrome. We investigated whether á-lipoic acid (ALA) exerts a lipidlowering effect through regulation of SIRT1 activation and production in C2C12 myotubes. Methods ALA-stimulated AMP-activated protein kinase (AMPK), acetyl-CoA carboxylase (ACC), adipose triacylglycerol lipase (ATGL) and fatty acid synthase (FAS) production, as well as intracellular triacylglycerol accumulation and fatty acid β-oxidation were analysed in the absence or presence of a SIRT1 inhibitor (nicotinamide), SIRT1 small interfering (si) RNA and an AMPK inhibitor (compound C) in C2C12 myotubes. Mice with streptozotocin/nicotinamideinduced diabetes and db/db mice fed on a high-fat diet were used to study the ALA-mediated lipid-lowering effects in vivo. Results ALA increased the NAD+/NADH ratio to enhance SIRT1 activity and production in C2C12 myotubes. ALA subsequently increased AMPK and ACC phosphorylation, leading to increased palmitate β-oxidation and decreased intracellular triacylglycerol accumulation in C2C12 myotubes. In cells treated with nicotinamide or transfected with SIRT1 siRNA, ALA-mediated AMPK/ACC phosphorylation, intracellular triacylglycerol accumulation and palmitate β-oxidation were reduced, suggesting that SIRT1 is an upstream regulator of AMPK. ALA increased ATGL and suppressed FAS protein production in C2C12 myotubes. Oral administration of ALA in diabetic mice fed on a high-fat diet and db/db mice dramatically reduced the body weight and visceral fat content. Conclusions/interpretation ALA activates both SIRT1 and AMPK, which leads to lipid-lowering effects in vitro and in vivo. These findings suggest that ALA may have beneficial effects in the treatment of dyslipidaemia and obesity.

AB - Aims/hypothesis Sirtuin 1 (SIRT1) is a longevity-associated protein, which regulates energy metabolism and lifespan in response to nutrient deprivation. It has been proposed to be a therapeutic target for obesity and metabolic syndrome. We investigated whether á-lipoic acid (ALA) exerts a lipidlowering effect through regulation of SIRT1 activation and production in C2C12 myotubes. Methods ALA-stimulated AMP-activated protein kinase (AMPK), acetyl-CoA carboxylase (ACC), adipose triacylglycerol lipase (ATGL) and fatty acid synthase (FAS) production, as well as intracellular triacylglycerol accumulation and fatty acid β-oxidation were analysed in the absence or presence of a SIRT1 inhibitor (nicotinamide), SIRT1 small interfering (si) RNA and an AMPK inhibitor (compound C) in C2C12 myotubes. Mice with streptozotocin/nicotinamideinduced diabetes and db/db mice fed on a high-fat diet were used to study the ALA-mediated lipid-lowering effects in vivo. Results ALA increased the NAD+/NADH ratio to enhance SIRT1 activity and production in C2C12 myotubes. ALA subsequently increased AMPK and ACC phosphorylation, leading to increased palmitate β-oxidation and decreased intracellular triacylglycerol accumulation in C2C12 myotubes. In cells treated with nicotinamide or transfected with SIRT1 siRNA, ALA-mediated AMPK/ACC phosphorylation, intracellular triacylglycerol accumulation and palmitate β-oxidation were reduced, suggesting that SIRT1 is an upstream regulator of AMPK. ALA increased ATGL and suppressed FAS protein production in C2C12 myotubes. Oral administration of ALA in diabetic mice fed on a high-fat diet and db/db mice dramatically reduced the body weight and visceral fat content. Conclusions/interpretation ALA activates both SIRT1 and AMPK, which leads to lipid-lowering effects in vitro and in vivo. These findings suggest that ALA may have beneficial effects in the treatment of dyslipidaemia and obesity.

KW - ́-lipoic acid

KW - AMPK

KW - ATGL

KW - SIRT1

UR - http://www.scopus.com/inward/record.url?scp=84865406937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865406937&partnerID=8YFLogxK

U2 - 10.1007/s00125-012-2530-4

DO - 10.1007/s00125-012-2530-4

M3 - Article

C2 - 22456698

AN - SCOPUS:84865406937

VL - 55

SP - 1824

EP - 1835

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 6

ER -